Acquiring Company
Supernus Pharmaceuticals
Acquired Company
Indivior Pharmaceuticals
RockvilleRichmondBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaBiotechnologyHealth CareMedicalPharmaceuticalDescription
Supernus Pharmaceuticals and Indivior Pharmaceuticals completed their merger on November 2, 2026, creating Supernus, Inc. (Nasdaq: SUPN) with an 11-product CNS portfolio. Former Indivior stockholders own about 56.5% of the combined company, and former Supernus stockholders own about 43.5%. Indivior stockholders also received a USD 1.0 billion special cash dividend, financed by a USD 650 million Citibank term loan and USD 350 million of existing cash.
Who to call at Supernus Pharmaceuticals, and when
When Supernus Pharmaceuticals changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Supernus Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Supernus Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Supernus Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Supernus Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Indivior Pharmaceuticals?
Indivior Pharmaceuticals was acquired by Supernus Pharmaceuticals, based in Rockville. The deal was reported on November 2, 2026. Supernus Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Supernus Pharmaceuticals is publicly traded (SUPN) and operates in Biotechnology.
When did Supernus Pharmaceuticals acquire Indivior Pharmaceuticals?
Supernus Pharmaceuticals's acquisition of Indivior Pharmaceuticals was reported on November 2, 2026. Supernus Pharmaceuticals and Indivior Pharmaceuticals completed their merger on November 2, 2026, creating Supernus, Inc. (Nasdaq: SUPN) with an 11-product CNS portfolio. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Indivior Pharmaceuticals do?
Indivior Pharmaceuticals, Inc. specializes in the treatment of addiction and is engaged in developing medicines to help individuals with substance use disorders. It is publicly traded (INDV), operating in Biotechnology, and is based in Richmond.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.